Implications of the success of EGFR-targeted therapy in advanced non-small cell lung cancer for its application to the adjuvant setting.

J Thorac Dis · 2020 · PMC7475551 · PMID 32944373

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although subset analysis showed a trend toward a better DFS in favor of erlotinib in patients with activating mutations of EGFR , the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.